Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

被引：0
|
作者：
Dhanashree Ratra
Krishnakanta Roy
Sneha Giridhar
Sushant Madaan
机构：
[1] Medical Research Foundation,Department of Vitreoretinal Diseases
[2] Sankara Nethralaya,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti VEGF; Biosimilar; Comparison with bevacizumab; DME; nAMD; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 149
页数：14
相关论文
共 50 条
  • [41] Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
    Joao Carrasco
    Georg-Alexander Pietsch
    Marie-Pierre Nicolas
    Cecile Koerber
    Craig Bennison
    Jisu Yoon
    Advances in Therapy, 2020, 37 : 300 - 315
  • [42] Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies
    Carrasco, Joao
    Pietsch, Georg-Alexander
    Nicolas, Marie-Pierre
    Koerber, Cecile
    Bennison, Craig
    Yoon, Jisu
    ADVANCES IN THERAPY, 2020, 37 (01) : 300 - 315
  • [43] INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT FOR RETINOPATHY OF PREMATURITY Comparison Between Ranibizumab and Bevacizumab
    Chen, San-Ni
    Lian, Iebin
    Hwang, Ya-Chi
    Chen, Yi-Hsing
    Chang, Yao-Chung
    Lee, Kun-Hsien
    Chuang, Chih-Chun
    Wu, Wei-Chi
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2015, 35 (04): : 667 - 674
  • [44] Luminous: Results from the 2014 Interim Analysis to Provide Further Real-World Evidence for Clinical Ranibizumab Use
    Brand, Christopher
    OPHTHALMOLOGICA, 2014, 232 : 4 - 5
  • [45] Visual outcomes, safety profile and morphometric response of optical coherence tomography biomarkers to ranibizumab biosimilar treatment in neovascular age-related macular degeneration: Real-world evidence
    Kelkar, Aditya S.
    Kelkar, Jai
    Bolisetty, Mounika
    Kelkar, Shreekant B.
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2021, 69 (06) : 1469 - 1474
  • [46] Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience
    James, Datta G. P.
    Mitkute, Doville
    Porter, Grazyna
    Vayalambrone, Deepak
    ASIA-PACIFIC JOURNAL OF OPHTHALMOLOGY, 2019, 8 (03): : 200 - 205
  • [47] Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
    Jin, Ran
    Ogbomo, Adesuwa S.
    Accortt, Neil A.
    Lal, Lincy S.
    Bishi, Geetanjali
    Sandschafer, Darcie
    Goldschmidt, Jerome H.
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
  • [48] Analysis of real-world treatment patterns in a matched rheumatology population that continued innovator infliximab therapy or switched to biosimilar infliximab
    Yazici, Yusuf
    Xie, Lin
    Ogbomo, Adesuwa
    Ellis, Lorie A.
    Goyal, Kavitha
    Teeple, Amanda
    Simsek, Ismail
    BIOLOGICS-TARGETS & THERAPY, 2018, 12 : 127 - 134
  • [49] Comparison of Corneal Endothelial Changes After a Single-Dose Injection of Bevacizumab or Ranibizumab
    Horozoglu, Fatih
    Gonen, Tansu
    Yasar, Mustafa
    Sever, Ozkan
    Keskinbora, Kadircan
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2013, 43 (06): : 391 - 394
  • [50] Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion
    Alex Yuan
    Baseer U.Ahmad
    David Xu
    Rishi P.Singh
    Peter K.Kaiser
    Daniel F.Martin
    Jonathan E.Sears
    Andrew P.Schachat
    Justis P.Ehlers
    International Journal of Ophthalmology, 2014, 7 (01) : 86 - 91
12345